EA201690557A1 - METHODS OF TREATING SYNDROME OF BRACKLE CHROMOSOME AND RELATED DISORDERS - Google Patents

METHODS OF TREATING SYNDROME OF BRACKLE CHROMOSOME AND RELATED DISORDERS

Info

Publication number
EA201690557A1
EA201690557A1 EA201690557A EA201690557A EA201690557A1 EA 201690557 A1 EA201690557 A1 EA 201690557A1 EA 201690557 A EA201690557 A EA 201690557A EA 201690557 A EA201690557 A EA 201690557A EA 201690557 A1 EA201690557 A1 EA 201690557A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
chromosome
brackle
related disorders
treating syndrome
Prior art date
Application number
EA201690557A
Other languages
Russian (ru)
Inventor
Ярон Дэниели
Далия Мегиддо
Original Assignee
Алкобра Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Алкобра Лтд. filed Critical Алкобра Лтд.
Publication of EA201690557A1 publication Critical patent/EA201690557A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Данное изобретение относится к способам ослабления признака или симптома синдрома ломкой Х-хромосомы и связанных с ним расстройств, таких как расстройства аутистического спектра.This invention relates to methods for attenuating the symptom or symptom of the fragile X chromosome syndrome and related disorders such as autism spectrum disorders.

EA201690557A 2013-09-09 2014-09-09 METHODS OF TREATING SYNDROME OF BRACKLE CHROMOSOME AND RELATED DISORDERS EA201690557A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Publications (1)

Publication Number Publication Date
EA201690557A1 true EA201690557A1 (en) 2016-07-29

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690559A EA201690559A1 (en) 2013-09-09 2014-09-09 METHODS FOR DETERMINING THE RESPONSE TO THERAPY
EA201690557A EA201690557A1 (en) 2013-09-09 2014-09-09 METHODS OF TREATING SYNDROME OF BRACKLE CHROMOSOME AND RELATED DISORDERS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690559A EA201690559A1 (en) 2013-09-09 2014-09-09 METHODS FOR DETERMINING THE RESPONSE TO THERAPY

Country Status (12)

Country Link
EP (2) EP3044589A1 (en)
JP (2) JP2016530291A (en)
KR (2) KR20160086818A (en)
CN (2) CN105917225A (en)
AU (2) AU2014315026A1 (en)
CA (2) CA2922901A1 (en)
EA (2) EA201690559A1 (en)
IL (2) IL244343A0 (en)
MX (2) MX2016003006A (en)
SG (2) SG11201601830PA (en)
TW (2) TW201605443A (en)
WO (2) WO2015033224A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431442B (en) * 2013-07-31 2018-08-07 Udc 爱尔兰有限责任公司 Luminous diaza benzo imidazole carbene metal complex
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (en) * 2017-03-24 2018-09-14 华东师范大学 A kind of self-closing disease sociability assessment system based on data analysis technique
EP3773538A1 (en) * 2018-04-13 2021-02-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (en) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 Pharmaceutical Composition for Improving Fragile X Syndrome Comprising Agmatine or its derivatives
CA3102786A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders
US20230024384A1 (en) * 2020-01-08 2023-01-26 Neuroventi Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders
KR102398219B1 (en) * 2020-02-07 2022-05-17 주식회사 뉴로벤티 Composition comprising rilmenidine compound for treating fragile x syndrome and related developmental disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (en) 1980-06-30 1986-06-25 Baldacci Lab Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOLIC INTOXICATIONS
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EA023758B1 (en) * 2009-06-25 2016-07-29 Алкобра Лтд. Use of metadoxine for treating attention deficit/hyperactivity disorder (adhd/add)

Also Published As

Publication number Publication date
CA2923421A1 (en) 2015-03-12
IL244453A0 (en) 2016-04-21
KR20160078956A (en) 2016-07-05
JP2016530536A (en) 2016-09-29
SG11201601830PA (en) 2016-04-28
TW201605443A (en) 2016-02-16
CN105517546A (en) 2016-04-20
AU2014315026A1 (en) 2016-03-24
SG11201601605YA (en) 2016-04-28
JP2016530291A (en) 2016-09-29
MX2016003002A (en) 2016-09-08
AU2014316779A1 (en) 2016-03-17
MX2016003006A (en) 2016-06-10
CN105917225A (en) 2016-08-31
WO2015035402A1 (en) 2015-03-12
WO2015033224A2 (en) 2015-03-12
WO2015033224A3 (en) 2015-07-02
CA2922901A1 (en) 2015-03-12
TW201606304A (en) 2016-02-16
EP3043792A2 (en) 2016-07-20
IL244343A0 (en) 2016-04-21
EP3044589A1 (en) 2016-07-20
KR20160086818A (en) 2016-07-20
EA201690559A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
EA201690557A1 (en) METHODS OF TREATING SYNDROME OF BRACKLE CHROMOSOME AND RELATED DISORDERS
EA201891251A1 (en) PAD4 BICYCLIC INHIBITORS
EA201891910A1 (en) PAD4 HETEROARYLINARY INHIBITORS
EA201792205A1 (en) HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201691594A1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS
EA201690881A1 (en) COMPOUNDS INHIBITORS AUTOTAXIN
EA201791460A1 (en) N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
EA201691272A1 (en) TETRAHYDROPYRIDOPIRASINES AS GPR6 MODULATORS
EA201791208A1 (en) Antibodies to CD38 for the treatment of acute myeloid leukemia
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201490030A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
TR201901886T4 (en) DNA-PK inhibitors.
EA201790266A1 (en) INDOLS FOR USE IN INFECTIONS CAUSED BY THE FLU VIRUS
EA201491151A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201891347A1 (en) Aza-benzimidazole inhibitors PAD4
EA201591889A1 (en) 6- (5-HYDROXY-1H-PYRAZOL-1-IL) NICOTINAMIDE PHD INHIBITORS
EA201890185A1 (en) METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID
EA201591360A1 (en) AZABENZIMADAZLES AS INHIBITORS INHIBITORS PDE4 FOR THE TREATMENT OF THE CNS AND OTHER DISORDERS
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
CU20150094A7 (en) SUBSTITUTED IMIDAZOPIRIDAZINAS
EA201792612A1 (en) 6-AMINOHINOLIN-3-CARBONITRILES AS COT MODULATORS
EA201600429A1 (en) METHOD OF CLEANING 2,5-DICHLOROPHENOL
EA201600026A1 (en) BACTERIAL HYALURONIDASE AND METHOD FOR ITS PRODUCTION
MY176049A (en) Serine/threonine kinase inhibitors